drugset / Trial / NCT01831232

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT01831232

NaSingle-groupOpen-labelTreatment

Summary

This clinical trial studies idarubicin, cytarabine, and pravastatin sodium in treating patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving idarubicin and cytarabine together with pravastatin sodium may kill more cancer cells.

Timeline

Start
2013-05
Primary completion
2015-02
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule
Subject Idarubicin Small molecule
Subject Pravastatin Small molecule Oral